The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ERCC1 and class III β-tubulin expression in chemotherapy-naive advanced non-small cell lung cancer patients treated with cisplatin and vinorelbine.
S. Park
No relevant relationships to disclose
J. C. Park
No relevant relationships to disclose
Y. J. Yang
No relevant relationships to disclose